他汀类药物对血脂异常患者睑板腺形态的影响
他汀组总睑板腺评分、上睑睑板腺评分、睑缘异常评分及睑脂质量均有统计学显著变化,非他汀组上睑睑板腺评分和睑脂质量也出现类似变化。结论认为即使使用他汀,血脂异常患者睑板腺萎缩和睑脂质量恶化仍在长期持续。
要点
- 他汀治疗组随访期间总睑板腺评分(P=.01)和上睑睑板腺评分(P=.012)有统计学显著变化。
- 他汀组睑缘异常评分(P=.0059)和睑脂质量(P=.0002)也有统计学显著变化。
- 非他汀组上睑睑板腺评分(P=.046)和睑脂质量(P=.046)出现类似变化,睑板腺萎缩与睑脂恶化长期持续。
核心结论
- 血脂异常患者即使接受他汀治疗,睑板腺萎缩和睑脂质量恶化在长期随访中仍持续存在。
研究设计与样本
- 组1为规律接受HMG-CoA还原酶抑制剂(他汀)治疗的血脂异常患者,组2为新诊断并接受生活方式干预的血脂异常患者。
- 在基线、6个月和12个月进行睑板腺照相并以睑板腺评分分级,同时行裂隙灯检查、眼表疾病指数问卷及干眼参数测量。
主要发现
- 他汀组随访期间总睑板腺评分(P=.01)、上睑睑板腺评分(P=.012)、睑缘异常评分(P=.0059)和睑脂质量(P=.0002)均有统计学显著变化。
- 非他汀组上睑睑板腺评分(P=.046)和睑脂质量(P=.046)出现类似变化。
临床怎么用
- 对血脂异常患者,即使正在使用他汀,也应长期关注睑板腺萎缩和睑脂质量恶化,并按需评估干眼相关指标。
局限性
- 本研究为非随机设计,原文未报告组间比较的统计学结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Previous studies have suggested an association between dyslipidemia and meibomian gland dysfunction (MGD). The aim of this prospective, nonrandomized clinical study is to evaluate the possible association of dyslipidemia and its treatment with meibomian gland (MG) morphologic changes by standardized meibography. DESIGN: Prospective, nonrandomized clinical study. METHODS: Two groups of participants were enrolled: group 1, comprised of patients under regular 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) treatment for dyslipidemia, and group 2, those with newly diagnosed dyslipidemia who were under lifestyle interventions. Meibography was performed at baseline and at both the 6- and 12-month visits and were graded by meiboscores. Participants underwent slit lamp examination for signs of changes in meibum quality and MG lid morphologic features. The Ocular Surface Disease Index questionnaire was given to measure subjective symptoms of ocular surface disease. Dry eye parameters including tear meniscus height, noninvasive first and average tear film break-up time, and Schirmer test results were also recorded. RESULTS: Ninety-eight participants completed this longitudinal study over 12 months. There were statistically significant changes in total meiboscores (P = .01) and upper eyelid meiboscores (P = .012), lid margin abnormality scores (P = .0059), and meibum quality (P = .0002) in the statin group during follow-up visits. Similar changes of upper eyelid meiboscores (P = .046) and meibum quality (P = .046) were noted in the nonstatin group. CONCLUSION: Meibomian gland atrophy and deterioration of meibum quality continued in the long term among participants with dyslipidemia even under statin usage.
引用
- Wu KI, Chen CY, Jou TS, et al. Effect of 3-Hydroxy-3-Methyl-Glutaryl-Coenzyme A Reductase Inhibitors on the Meibomian Gland Morphology in Patients with Dyslipidemia. Am J Ophthalmol. 2020. PMID: 32621892. doi:10.1016/j.ajo.2020.06.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。